Literature DB >> 33167719

Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort.

Charlotte Madsen1, Trine Lindhardt Plesner2, Hans Herluf Bentzen1, Judit Jørgensen1, Ida Blok Sillesen1, Bodil M Himmelstrup3, Pär Josefsson4, Torben Plesner5, Tine Litske Bennedsen6, Maja Ludvigsen1,7, Francesco A d'Amore1.   

Abstract

We investigated incidence, risk factors and outcome for follicular lymphoma (FL) patients with histologic transformation (HT) found at primary diagnosis (discordant/composite, dc-tFL) or sequentially (s-tFL). Between 2000 and 2015, 2773 patients were identified. The majority of patients (2252, 81%) did not experience HT (nt-FL), while 224 (8%) had dc-tFL and 297 (11%) s-tFL. The risk of HT was 2.2% per year and 9.6% at 5 years. Age ≥60, a high FLIPI risk score and LDH-elevation were associated with increased risk of HT. Calculated from primary diagnosis and compared with nt-FL, 5-year overall survival (OS) was inferior in both s-tFL and dc-tFL (nt-FL: 82%, s-tFL: 68%, dc-tFL: 68%; p = .001), whereas 5-year progression-free survival (PFS) was worse only in s-tFL (s-tFL: 18%, dc-tFL: 58%, nt-FL: 60%). Calculated from time of HT, s-tFL had inferior outcome compared to dc-tFL for both OS (s-tFL: 47%, dc-tFL: 68%, p = .001) and PFS (s-tFL: 35%, dc-tFL: 58%, p = .001).

Entities:  

Keywords:  Rituximab era; follicular lymphoma; transformation

Mesh:

Substances:

Year:  2020        PMID: 33167719     DOI: 10.1080/10428194.2020.1779254

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.

Authors:  Zhenjie Qu; Tingting Zhang; Fenghua Gao; Wenchen Gong; Yaoli Cui; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Bin Meng; Xiubao Ren; Lanfang Li; Xianhuo Wang; Huilai Zhang
Journal:  Biomed Res Int       Date:  2022-05-24       Impact factor: 3.246

2.  PD-1 Expression in Pre-Treatment Follicular Lymphoma Predicts the Risk of Subsequent High-Grade Transformation.

Authors:  Marie Beck Enemark; Ida Monrad; Charlotte Madsen; Kristina Lystlund Lauridsen; Bent Honoré; Trine Lindhardt Plesner; Stephen Jacques Hamilton-Dutoit; Francesco d'Amore; Maja Ludvigsen
Journal:  Onco Targets Ther       Date:  2021-01-18       Impact factor: 4.147

3.  Tumor-Tissue Expression of the Hyaluronic Acid Receptor RHAMM Predicts Histological Transformation in Follicular Lymphoma Patients.

Authors:  Marie Beck Enemark; Trine Engelbrecht Hybel; Charlotte Madsen; Kristina Lystlund Lauridsen; Bent Honoré; Trine Lindhardt Plesner; Stephen Hamilton-Dutoit; Francesco d'Amore; Maja Ludvigsen
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

4.  Primary Gastrointestinal Follicular Lymphomas: A Prospective Study of 31 Patients with Long-term Follow-up Registered in the French Gastrointestinal Lymphoma Study Group (GELD) of the French Federation of Digestive Oncology (FFCD).

Authors:  Tamara Matysiak-Budnik; Philippe Jamet; Nicolas Chapelle; Bettina Fabiani; Paul Coppo; Agnès Ruskoné-Fourmestraux
Journal:  Gut Liver       Date:  2022-03-15       Impact factor: 4.519

5.  Significance of initial, interim and end-of-therapy 18F-FDG PET/CT for predicting transformation risk in follicular lymphoma.

Authors:  Mixue Xie; Lulu Wang; Qi Jiang; Xuxia Luo; Xin Zhao; Xueying Li; Jie Jin; Xiujin Ye; Kui Zhao
Journal:  Cancer Cell Int       Date:  2021-07-26       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.